65,437 trials
Covid19
Primary: Proportional Change in D-dimer Level From Baseline to Day 8, or Day of Discharge if Prior to Day 8 (Phase 2b) — 137; 41.4; 34.7 Percent change — p=0.4715
Medication Adherence · Glaucoma
Primary: Compliance Percentage — 73.9; 94.6; 93.99 percentage of days dose monitor recorded
Neurologic Disorder · Chronic Disease · Pediatric Disorder
Primary: Global Symptom Score — 12.1 score on a scale
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Diabetes Mellitus, Type 2
Primary: Documentation of Diabetes Goal — 21; 27; 29; 23 Participants — p=<0.01
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Surgery · Bispectral Index
Primary: BIS Montage — 0.01 units on a scale
Diabetes Mellitus, Type 2 · Penile Diseases
Primary: Penile Length Change Between Baseline and Month 6 — 0; 0.5; 0.5; 0.8 Median change from baseline (cm)
Nicotine Dependence
Primary: Client Reported Tobacco Medications — 48; 28; 62; 24 Participants
Attention Deficit Disorder With Hyperactivity
Primary: Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Total Score Change From End of Open Label Phase (Baseline) to End of…
Breast Feeding
Primary: Perception of Milk Supply — 54.9; 56.2 score on a scale — p=.272
Tattoo Removal
Primary: Level of Tattoo Clearing at 12 Weeks for Each Treatment Arm as Assessed by the Blinded Reviewers. — 3; 3 score on a scale
Chronic Hepatitis D Infection
Primary: ≥2 log10 Decline of HDV RNA From Baseline at End of Treatment (EOT) — 1; 0; 1; 0 Participants
Body Fat
Primary: Change of Thigh Circumference From Baseline — .98; .32 cm
Acute Myeloid Leukemia
Primary: Time (Days) to Transfusion-independent Platelet Recovery (Platelet Counts Values ≥ 20,000/μL and ≥ 50,000/μL Without a Platelet Transfusion) — 21.3; 23.1 days